Glycopegylated FGF21 analog

Pegozafermin is a long-acting FGF21 analog engineered with sugar-linked PEG so it can be dosed once weekly or every two weeks instead of the near-daily injections that killed earlier FGF21 candidates [1][9]. Originally developed by 89bio (Nasdaq: ETNB), the program was acquired by Roche in a merger announced September 17, 2025 and closed October 30, 2025 for $14.50 per share in cash plus a contingent value right of up to $6.00 per share, valuing the deal at up to approximately $3.5 billion on a fully diluted basis [8]. The molecule is now advancing under Roche in three Phase 3 trials: ENTRUST for severe hypertriglyceridemia (enrollment complete, n=369, topline guided for Q1 2026) and two ENLIGHTEN studies in MASH (formerly NASH), one in pre-cirrhotic F2/F3 fibrosis (n=1,350) and one in compensated cirrhosis (n=762) [2][3][4]. Direct comparators include Akero's efruxifermin (the other lead FGF21 analog with strong Phase 2 biopsy data), Madrigal's approved oral resmetirom (Rezdiffra), Inventiva's lanifibranor (NATIVE Phase 3, pan-PPAR), and the incretin wave of semaglutide and tirzepatide, both of which are producing meaningful liver-fat and fibrosis effects in MASH populations [5][15]. The unresolved question is whether an injectable FGF21 can carve durable share against the oral and once-weekly incretin options that patients may already be taking for obesity or diabetes.

Novel compound. Not approved for any indication anywhere in the world. Pegozafermin holds FDA Breakthrough Therapy designation in MASH (granted on the strength of the Phase 2b ENLIVEN histology data) and Fast Track for severe hypertriglyceridemia [6]. Corporate status changed materially in September 2025: the September 17, 2025 8-K disclosed a definitive merger agreement with Roche at $14.50 per share plus a $6.00 CVR, and the transaction closed October 30, 2025, making 89bio a wholly owned subsidiary of Roche [8]. All three Phase 3 programs continue under Roche sponsorship. ENTRUST (NCT05852431) enrolled 369 patients (30 mg QW, 20 mg QW, or placebo in a 3:3:2 ratio) with a 26-week primary endpoint of percent change in fasting triglycerides versus placebo [3]. Enrollment completed December 2024 and topline was guided by 89bio for Q1 2026 - as of this writeup, the definitive topline announcement had not been confirmed in our source search; investors should verify current Roche disclosures before relying on ENTRUST status. ENLIGHTEN-Fibrosis (NCT06318169) is enrolling roughly 1,350 patients with F2/F3 MASH, with the Week 52 histology cut driving the accelerated-approval filing package [2]. ENLIGHTEN-Cirrhosis (NCT06419374) is a separate 762-patient study in compensated cirrhosis (F4), aiming for full approval on fibrosis regression [4]. The Week 52 biopsy readout from ENLIGHTEN-Fibrosis is the value-defining data point for the program and remains guided to 2027.

FGF21 is a hormone the liver makes when it senses metabolic stress. Think of it as a message telling fat cells to burn energy, telling muscle to take up glucose, and telling the liver itself to stop packaging fat into triglycerides and shipping them out. In MASH and severe hypertriglyceridemia, this signaling is blunted, so fat piles up in the liver and triglycerides flood the bloodstream. Pegozafermin is a synthetic copy of FGF21 with sugar chains and a PEG polymer bolted on. That modification does two things: it slows kidney clearance so the drug lasts a week or two per shot, and it preserves binding to the KLB co-receptor, the partner protein FGF21 needs to activate FGFR1c on target tissues [9]. Biologically the target is well-validated. Mice and monkeys given FGF21 lose liver fat, lower triglycerides, and improve insulin sensitivity. Human genetics agree: FGF21 pathway variants track with metabolic disease [10]. What killed prior FGF21 drugs was not the biology but the pharmacology. First-generation molecules (LY2405319, PF-05231023) had short half-lives and injection-site problems. Pegozafermin and Akero's efruxifermin were both designed to fix that. In the Phase 2b ENLIVEN trial (Loomba et al., NEJM 2023), 44 mg every two weeks delivered 27% fibrosis improvement of at least one stage without worsening NASH and 26% NASH resolution without worsening fibrosis at Week 24, versus 7% and 2% for placebo respectively [11]. The 30 mg weekly arm delivered 26% fibrosis improvement and 23% NASH resolution. Both actively dosed arms cleared the bar for a Phase 3 push.

ENLIGHTEN-Fibrosis (NCT06318169) is the value driver: 1,350 patients with biopsy-confirmed MASH and F2 or F3 fibrosis, randomized to pegozafermin (two doses) or placebo, with the Week 52 primary endpoint being fibrosis improvement of at least one stage without worsening of steatohepatitis, matching the endpoint the FDA accepted for resmetirom's accelerated approval [2][14]. A parallel co-primary of MASH resolution without worsening fibrosis supports the label. Enrollment is active. ENLIGHTEN-Cirrhosis (NCT06419374) enrolls 762 F4 patients (compensated cirrhosis) with a much harder endpoint: fibrosis regression, a bar few MASH drugs have cleared [4]. This is the full-approval path and where the mechanism gets its toughest biology test, since cirrhotic livers scar in ways that may not reverse regardless of upstream metabolic correction. ENTRUST (NCT05852431) enrolled 369 patients with severe hypertriglyceridemia (fasting TG 500 to 2,000 mg/dL) for a 26-week primary endpoint of percent change in fasting triglycerides versus placebo, a straightforward pharmacodynamic readout that Phase 2 (ENTRIGUE, NCT04541186) had already delivered with roughly 57 to 63% median TG reductions in pooled and top-dose analyses [12][3]. Trial design across the program is conventional and well-powered. The risk is not statistical, it is biological: whether biopsy improvement at 52 weeks translates to hard outcomes payers will pay for.

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is concentrated in the cirrhosis trial. F4 MASH has broken drugs that looked strong in earlier fibrosis stages (selonsertib, cenicriviroc, obeticholic acid all missed there), and the fibrosis-regression endpoint is unforgiving [13]. Safety risk in the FGF21 class centers on GI tolerability (nausea, diarrhea) and injection-site reactions, which drove earlier candidates out of development. Pegozafermin's Phase 2 tolerability was acceptable but not clean, and a 52-week exposure in 1,350+ patients will surface any low-frequency signals not seen in smaller Phase 2b cohorts [11]. There is also a modest signal of small LDL-C and bone turnover marker changes in FGF21 studies that regulators will scrutinize. Competitive risk is the sharper knife. Resmetirom launched in 2024 as an oral once-daily drug with MAESTRO-NASH Phase 3 data of 25 to 26% fibrosis improvement (vs 14% placebo) and 26 to 30% NASH resolution (vs 10% placebo), and is capturing early MASH prescribers [14]. Semaglutide showed positive MASH histology in the ESSENCE trial and Novo Nordisk is pursuing an indication; tirzepatide's SYNERGY-NASH also hit [5]. Both incretins will be prescribed for obesity and diabetes regardless of MASH labeling, giving them a coverage and access moat pegozafermin cannot easily out-market. Inventiva's lanifibranor (pan-PPAR agonist) is the other Phase 3 asset targeting the same F2/F3 biopsy population as ENLIGHTEN-Fibrosis via the NATIVE Phase 3 program, and its readout is a direct read-across that will move the market for all MASH candidates [15]. Payer willingness to add a specialty injectable on top of a GLP-1 already in the patient's regimen is the sober question Roche has to answer post-approval. Execution risk on cash runway is materially reduced by the Roche acquisition: prior to the deal, 89bio held $561.2 million in cash and marketable securities at Q2 2025 with a quarterly net loss of $111.5 million; under Roche the program is now funded from parent-company operating cash flow rather than dilutive equity raises [8].

Worth watching, and the highest-signal upcoming data point in the MASH space outside the incretin readouts. ENLIGHTEN-Fibrosis Week 52 biopsy is the readout that resets the program's clinical and commercial trajectory in either direction. A fibrosis-improvement rate in the 25 to 30% range, cleanly above placebo, would justify accelerated-approval filing and validate the FGF21 class as a legitimate second pillar of MASH treatment alongside resmetirom (Rezdiffra), which works via a different liver target (thyroid hormone receptor beta). Anything under 20% or with meaningful placebo overlap makes the injectable-versus-oral competitive argument nearly impossible to win. The SHTG readout from ENTRUST is a secondary but genuine commercial optionality - investors should confirm the Q1 2026 topline status via current Roche disclosures before relying on it [3]. On the corporate side, the pegozafermin thesis is no longer an 89bio call option: 89bio was acquired by Roche at $14.50 cash plus a $6.00 CVR per share (up to $3.5 billion), closed October 30, 2025, so incremental upside for former shareholders now sits in the CVR milestone structure rather than equity beta [8]. Cross-watch Akero's SYMMETRY Phase 3 efruxifermin data as the primary read-across: if efruxifermin hits or misses in F4 cirrhosis, that will move the probability on ENLIGHTEN-Cirrhosis materially in the same direction. Also cross-watch Inventiva's NATIVE Phase 3 lanifibranor readout - if it reads before ENLIGHTEN-Fibrosis, it will reset expectations for the F2/F3 biopsy endpoint across the space [15].